Director, Late Stage Clinical Development

Definium Therapeutics is a late-stage clinical biopharmaceutical company and our mission is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale.

Our leadproductcandidate,lysergidetartrate(our proprietary orally disintegrating tablet form oflysergide(LSD) D-tartrate),represents a highly differentiated, potential best-in-class opportunity for patients suffering from generalized anxiety, major depressive disorder, and posttraumatic stress disorder. Our early stage pipeline includes DT402, the R-enantiomer of MDMA and is under development to target the core symptoms of autism spectrum disorder (ASD), specifically addressing social communication challenges.

Guided bythe recognition that patients deserve more than better, Definium is relentlessly advancing a new generation of therapeutics intended to addresstheunderlying causes of psychiatric and neurological disorders. By turning evidence into impact, Definium aims to change the trajectory of today’s mental health care crisis and enable a healthier future. Headquartered in New York, Definium Therapeutics trades on Nasdaq under the symbol DFTX.

Together we are moving psychiatry forward-beyond better, into a boundless future. Join us!

The Director, Late-Stage Clinical Strategy will be responsible for the
end-to-end strategy development, design, and execution of Expanded Access Programs and Late-Stage studies across Definium's portfolio. This leader will provide support to ensure programs are scientifically sound, operationally feasible, regulator-ready, and aligned with the integrated asset strategy, including lifecycle management, real-world evidence generation, and post-approval commitments.

This role requires both strategic leadership and hands-on execution
, with the ability to operate effectively in a lean, fast‑moving organization.

• Lead aspects of the global strategy for Expanded Access Programs and Late
  - Stage development
  , aligned with asset lifecycle objectives, patient access goals, and regulatory expectations
• Partner with the Executive Director Late-Stage Clinical Strategy, Clinical Development, Clinical Operations, HEOR, Medical Affairs, Regulatory Affairs, Commercial, Asset Strategy Lead and Program Leadership to ensure Expanded Access Program and Late-Stage clinical activities are fully integrated into the overall asset strategy

• Lead the development and implementation of Expanded Access Programs, including protocol development, eligibility criteria, safety oversight, and operational execution
• Collaborate with cross-functional planning team to ensure Expanded Access Programs are compliant, scalable, ethically sound, and aligned with regulatory guidance
• Provide consultation to benefit-risk assessment, safety monitoring, and ongoing program evaluation

• Support the development of the late-stage clinical evidence generation strategy objectives, including real-world evidence generation, long-term safety, effectiveness, and differentiation in the treatment landscape
• Lead the design, planning, and execution of the late-stage clinical evidence program, including protocol development, data collection strategies, and interpretation of outcomes for Phase 4 and investigator-initiated trials.
• Ensure late-stage clinical program designs address regulatory commitments, payer needs, and scientific gaps

• Collaborate in the preparation and review of clinical content for regulatory submissions and interactions as applicable
• Provide clinical input into Investigator Brochures, clinical study reports, in collaboration with Regulatory Affairs

• Work collaboratively with Clinical Operations, Clinical Development, Data Management, Biostatistics, Pharmacovigilance, and Project Management to ensure high-quality execution
• Establish and maintain relationships with key investigators, advisors, and external experts to support EAP and late stage/potentially Phase 4 objectives
• Provide clinical leadership within matrix…